AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

In the closing of the recent trading day, Astrazeneca (AZN) stood at $66.54, denoting a +0.03% change from the preceding trading day.

Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Astrazeneca (AZN) is a Top-Ranked Value Stock: Should You Buy?

Gilead Sciences

Merck

By Feb. 1, the federal government will send an initial offer for each of the 10 drugs selected for the first round of negotiations under the program, which was established under the Inflation Reduction Act and touted by President Joe Biden as part of a broader effort to drive down healthcare costs. Yet several lawsuits challenging the program could also reach turning points in the coming months, raising the prospect that some elements of the program could be stalled before they get off the ground.

Medicare drug price negotiations hit critical phase

GlaxoSmithKline

UBS has revised its stance on two major UK-listed pharma companies - GSK PLC (LSE:GSK, NYSE:GSK) and AstraZeneca PLC (LSE:AZN) - with an upgrade for the former and a downgrade for the latter. GSK is moved from 'sell' to 'buy,' while the investment bank's call on AZ moves in the opposite direction.

GSK and AstraZeneca: A leading investment bank gives its verdict with an upgrade and a downgrade

London Stock Exchange Group PLC

Over 300 companies, including AstraZeneca, Anglo American, Endeavour Mining, Heathrow Airport and British American Tobacco, will start to include nature-related disclosures as part of their annual corporate reporting. Some of the early-adopter companies, which have a combined value of US$4 trillion, have committed to begin reporting on nature-related issues in their 2023 results, while others will start with their 2024 or 2025 results, it was announced as the agreement was formalised at the Davos summit today.

AstraZeneca, LSE and Heathrow among 320 co's to make nature-based disclosures in financial results

UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.

Sell AstraZeneca, says UBS, which upgrades European rivals including GSK

Drugmaker AstraZeneca has not seen any supply issues so far due to Red Sea shipping disruptions, a top executive told Reuters ahead of the World Economic Forum (WEF) on Monday.

AstraZeneca says no supply snags so far from Red Sea disruptions

JP Morgan has maintained its bullish stance on AstraZeneca PLC (LSE:AZN) in the wake of the San Francisco healthcare conference it sponsors. Repeating its overweight stance £130 a share price target, the US bank provided its assessment of a Q&A session fronted by AZ's CFO Aradhana Sarin, which presented a robust outlook for the company.

AstraZeneca: Leading bank bullish after key conference appearance

Amgen

Eli Lilly

Novo Nordisk

The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity.

FDA Finds No Link Between Obesity Drugs and Suicidal Thoughts

Astrazeneca (AZN) closed at $69.18 in the latest trading session, marking a -0.56% move from the prior day.

Here's Why Astrazeneca (AZN) Fell More Than Broader Market

U.K.-based AstraZeneca PLC NASDAQ: AZN is up 8.95% in the past month as investors grow optimistic about the company's improved earnings outlook for 2024. Not only are sales of cancer and diabetes drugs growing fast, but the company announced an acquisition in the area of innovative cell therapies.

AstraZeneca: Rebound in 2024 with double-digit earnings growth

Compugen

HOLON, Israel , Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen is entitled to receive a $10 million milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN), after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig.

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

The latest trading day saw Astrazeneca (AZN) settling at $68.38, representing a -0.58% change from its previous close.

Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know

AbbVie

Bristol-Myers

Cerevel Therapeutics Holdings Inc

Horizon Pharma

ImmunoGen

Karuna Therapeutics Inc

Mirati Therapeutics

Pfizer

Roche Holding AG

RayzeBio Inc

Seagen

CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.

Cramer names biopharma companies to watch as industry mergers start to pile up

BOSTON & ST. LOUIS--(BUSINESS WIRE)--Omniose, a preclinical biotechnology company, today announced an exclusive collaboration agreement with AstraZeneca to research potential vaccines for bacterial pathogens in AstraZeneca's early Vaccines & Immune Therapies pipeline. Under the terms of the agreement, AstraZeneca will have exclusive rights to Omniose's proprietary bioconjugation platform for up to three years, which allows for the development of high-quality vaccines against a range of bact.

Omniose Announces Scientific Collaboration With AstraZeneca to Research Vaccines for Serious Bacterial Diseases

LONDON & BUDAPEST, Hungary--(BUSINESS WIRE)--Turbine, a leading biological simulation company building a platform for interpreting human biology in silico, today announced it has entered into a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical company. Turbine will use its proprietary Simulated Cell™ platform to identify and understand mechanisms of resistance to therapy in hematological cancers. The collaboration will focus on understanding resistance mechanisms.

Turbine Announces Collaboration to Uncover Biological Mechanisms of Drug Resistance in Hematological Cancers

Astrazeneca (AZN) reachead $68.78 at the closing of the latest trading day, reflecting a +0.67% change compared to its last close.

Why the Market Dipped But Astrazeneca (AZN) Gained Today

Chevron

Amdocs

Barrick Gold

Lockheed Martin

Scorpio Tankers

Vale S.A.

I believe that 2024 will be good for equities. Potential rate cuts are a big impending catalyst.

7 Dividend-Paying Stocks To Add To Your Income Portfolio In 2024

GSK PLC (LSE:GSK, NYSE:GSK) shares got a shot in the arm this morning after Jefferies took a more positive view of the pharmaceuticals giant. The US investment bank upgraded its rating to ‘buy' from ‘hold' and increased its price target to 1,900p from 1,550p.

GSK gets shot in arm from upgrade, AstraZeneca mixed reviews after China deal

C4X Discovery Holdings PLC (AIM:C4XD) has reached what has been described as a "significant milestone" after receiving an $11 million payment under its $402 million deal with pharma giant AstraZeneca PLC (LSE:AZN). Specifically, the financial landmark marks the progression of the NRF2 Activator programme, created by C4XD and outlicensed to AZ.

C4X Discovery receives $11m AstraZeneca milestone payment

NATICK, Mass. , Jan. 2, 2024 /PRNewswire/ -- Allorion Therapeutics ("Allorion"), a US and China-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune diseases, has entered into an exclusive option and global license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor, as a potential new treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC).

Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca

Sanofi

AstraZeneca and Sanofi's respiratory syncytial virus (RSV) immunization for infants has been approved in China, the London-listed drugmaker said on Tuesday.

AstraZeneca, Sanofi's RSV infant shots approved in China

Astrazeneca (AZN) closed the most recent trading day at $67.35, moving +0.07% from the previous trading session.

Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note

AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.

AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion

AstraZeneca PLC (LSE:AZN) is set to acquire Gracell Biotechnologies, the Chinese company specialising in innovative cancer and autoimmune disease treatments, for US$1.2 billion The US$2 per share acquisition provides AstraZeneca access to platforms potentially shortening manufacturing times and enhancing the development of more efficient cell therapy treatments. Gracell's T-cell therapy, GC012F, is particularly promising for blood cancers and Lupus.

AstraZeneca to buy Chinese drug firm in billion dollar deal

News for AstraZeneca Stock (AZN)